An IFN-γ-IL-18 Signaling Loop Accelerates Memory CD8+ T Cell Proliferation by Iwai, Yoshiko et al.
An IFN-c-IL-18 Signaling Loop Accelerates Memory CD8
+
T Cell Proliferation
Yoshiko Iwai
1,2, Hiroaki Hemmi
1,2, Olga Mizenina
1, Shoko Kuroda
2, Koji Suda
1, Ralph M. Steinman
1*
1Laboratory of Cellular Immunology and Physiology, The Rockefeller University, New York, New York, United States of America, 2Medical Top Track (MTT) Program,
Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
Abstract
Rapid proliferation is one of the important features of memory CD8
+ T cells, ensuring rapid clearance of reinfection.
Although several cytokines such as IL-15 and IL-7 regulate relatively slow homeostatic proliferation of memory T cells during
the maintenance phase, it is unknown how memory T cells can proliferate more quickly than naı ¨ve T cells upon antigen
stimulation. To examine antigen-specific CD8
+ T cell proliferation in recall responses in vivo, we targeted a model antigen,
ovalbumin(OVA), to DEC-205
+ dendritic cells (DCs) with a CD40 maturation stimulus. This led to the induction of functional
memory CD8
+ T cells, which showed rapid proliferation and multiple cytokine production (IFN-c, IL-2, TNF-a) during the
secondary challenge to DC-targeted antigen. Upon antigen-presentation, IL-18, an IFN-c-inducing factor, accumulated at
the DC:T cell synapse. Surprisingly, IFN-c receptors were required to augment IL-18 production from DCs. Mice genetically
deficient for IL-18 or IFN-c-receptor 1 also showed delayed expansion of memory CD8
+ T cells in vivo. These results indicate
that a positive regulatory loop involving IFN-c and IL-18 signaling contributes to the accelerated memory CD8
+ T cell
proliferation during a recall response to antigen presented by DCs.
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Introduction
Memory CD8
+ T cells are an important component of acquired
immunity to viruses and other pathogens [1–3]. Memory T cells
can persist for extended periods, and they respond more rapidly
and more vigorously than naı ¨ve T cells when they reencounter the
same antigen. Although several cytokines such as IL-15 and IL-7
regulate basal, relatively slow, homeostatic proliferation of
memory T cells during the maintenance phase [4–8], it is
unknown how memory T cells can proliferate more quickly than
naı ¨ve T cells upon antigen re-encounter.
Memory T cells have been divided into ‘‘central’’ memory
(TCM) and ‘‘effector’’ memory (TEM) subsets [2,9]. TCM express
CD62L and CCR7, which allow efficient homing to lymph nodes,
whereas TEM lack expression of these lymph node-homing
receptors and are located in the blood, spleen, and nonlymphoid
tissues. TEM exhibit immediate effector activity, such as the
production of IFN-c and exertion of cytotoxic activity, whereas
TCM have greater proliferative potential upon antigen re-
encounter. Understanding the development of memory CD8
+ T
cells in response to safe forms of microbial and tumor antigens
should be valuable for identifying correlates of protective
immunity and the design of effective vaccines.
Immunization of mice with DCs that have been prepared and
loaded with antigen in vitro generates antigen-specific CD8
+
memory T cells [10,11], while in vivo depletion of DCs reduces
the capacity of mice to generate both primary and memory CD8
+
T cell responses [12]. Recently, it has become feasible to selectively
target antigens to DCs within intact lymphoid tissues and then
examine the function of these antigen presenting cells directly in
vivo, e.g., by incorporating the antigen within monoclonal
antibodies (mAbs) to DEC-205/CD205, an endocytic receptor
that is abundant on DCs within the T cell areas of lymphoid
organs [13–15]. Antigen targeting results in two distinct types of
primary response in the first 2–3 weeks following immunization:
deletional T cell tolerance in the steady state, and T cell immunity
following ligation of CD40 and the differentiation or maturation of
the DCs [14,15]. In the latter instance, the directed delivery of
antigens to DCs greatly amplifies the efficiency and magnitude of
the T cell response to peptides and protein antigens relative to
nontargeted antigen [16–18], making it attractive to use directed
antigen delivery to analyze the function of DCs in establishing
memory in a naı ¨ve animal using defined antigens and maturation
stimuli.
In this study we examined the generation of memory CD8
+ T
cells from the endogenous repertoire of normal mice following in
vivo delivery of ovalbumin (OVA) via a mAb to DEC-205. We
show that delivery of OVA to DEC-205
+ DCs with CD40 ligation
induces functional memory CD8
+ T cells. Interestingly, IFN-c
signaling stimulates DCs to produce IL-18, which was originally
identified as a stimulator of IFN-c production [19,20]. We show
that this positive regulatory loop of IFN-c-IL-18-signaling plays an
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2404important role in the acceleration of memory CD8
+ T cell
expansion during a secondary response to antigen presented by
DCs.
Results
DEC-205 targeting with CD40 ligation expands memory
CD8
+ T cells
To examine whether the targeted delivery of OVA to DEC-
205
+ DCs can induce memory CD8
+ T cells, C57BL/6(B6) mice
were primed with a single dose of anti-DEC-205:OVA protein in
the presence of the agonistic anti-CD40 mAb, 1C10 [21], and 60
days later, the mice were boosted with anti-DEC:OVA+anti-
CD40. At various time points after boosting, splenocytes were
isolated and stained with MHC tetramer (Fig. 1A). In a primary
response (in mice primed with PBS), OVA-specific CD8
+ T cells
appeared at day 5 and reached a peak at day 7. In recall responses
(in mice primed with anti-DEC:OVA+anti-CD40), OVA-specific
CD8
+ T cells reached a peak more rapidly in spleen, at day 4.
Fig. 1B summarizes the total numbers of tetramer
+ cells per spleen
in several experiments and shows the more rapid secondary
response. The rapid kinetics of the antigen-specific CD8
+ T cell
response was also observed in liver (Fig. 1C and D). The secondary
expansion of tetramer
+ CD8
+ T cells was not observed in the
absence of anti-CD40 during booster immunization (data not
shown). These results indicate that delivery of OVA to DEC-205
+
DCs in the presence of CD40 ligation induces expansion of
tetramer binding memory CD8
+ T cells in both spleen and liver,
and that these T cells respond rapidly to antigen rechallenge.
DEC-205 targeting with CD40 ligation induces memory
CD8
+ T cells in multiple peripheral tissues
We phenotyped the CD8
+ tetramer
+ T cells 60 days after
immunization with anti-DEC:OVA+ anti-CD40. The tetramer
binding cells had a memory phenotype, i.e., CD27
+, CD127
+ with
higher levels of CD44, CD122 and VLA-4 than naı ¨ve CD8
+ T
cells (Fig. 2A). They were mixture of two populations, CD62L high
and low (Fig. 2A). After 60 days of priming with anti-
DEC:OVA+anti-CD40 (but prior to boosting) tetramer
+ cells
were also detected in mucosal tissues such as lung and intestinal
epithelium and lamina propria, and also in Peyer’s patches (PP),
mesenteric lymph nodes (MLN), and spleen (Fig. 2B). These
memory cells were not found in peripheral tissues if mice were
primed with anti-DEC:OVA without anti-CD40 (data not shown).
Therefore targeting of OVA to DCs in the presence of anti-CD40
generates memory CD8
+ T cells in multiple peripheral tissues.
Memory CD8
+ T cells can proliferate more rapidly than
naı ¨ve T cells
To compare the proliferative capacity of naive and memory T
cells, mice were primed with PBS or anti-DEC:OVA+anti-CD40,
and boosted with anti-DEC:OVA+anti-CD40 at day 60. At day 2,
4, and 7 after boosting, splenocytes were isolated, labeled with
CFSE, and then cultured in vitro for 3 days in the absence or
presence of OVA257-264 peptide (Fig. 3A). T cell proliferation
was monitored by CFSE dilution. It has been shown that,
following CD8
+ T cell activation, daughter cells continue to divide
in the absence of further antigenic stimulation [22,23]. Fig.3B
shows T cell division in the absence of added antigen in vitro,
whereas Fig.3C shows expansion when the cells re-encounter the
same antigen in culture. In the mice primed with anti-
DEC:OVA+anti-CD40, T cell division was observed at day 2
without further addition of antigen, but it stopped at day 4 after
boosting (Fig. 3B). However, these memory T cells had greater
proliferative capacity, when they reencountered OVA in culture at
day 4 and 7 after boosting (Fig. 3C). In the primary response (in
mice primed with PBS), T cell division was detectable at day 4 but
not at day 7 (Fig. 3B), and antigen-driven expansion was observed
at later time point, at day 7 (Fig. 3C). These data indicate that
memory T cells can proliferate more rapidly than naı ¨ve T cells.
Memory CD8
+ T cells primed with anti-CD40 produce
multiple cytokines
Next we compared the capacity of primed CD8
+ T cells to
produce cytokines during a secondary or memory response (Fig. 4).
Mice were primed with PBS, or anti-DEC:OVA+anti-CD40, and
boosted with anti-DEC:OVA+anti-CD40 at day 60. The OVA-
specific CD8
+ IFN-c
+ T cells that had been primed with anti-
DEC:OVA+anti-CD40 allowed for strong IL-2 and TNF-a
production upon secondary challenge. In the primary response
(mice primed with PBS), the OVA-specific CD8
+ IFN-c
+ T cells
also produced some IL-2 and TNF-a although much less than
observed with memory cells. Therefore priming with anti-
DEC:OVA and agonistic anti-CD40 mAb generates memory
cells with the capacity to produce high levels of multiple cytokines.
Memory CD8
+ T cells primed with anti-CD40 exhibit
direct cytotoxicity and protective immunity
To examine the in vivo cytolytic function of the memory T cells,
mice were primed with PBS or anti-DEC:OVA+anti-CD40, and
boosted with PBS or anti-DEC:OVA+anti-CD40 at d 60 (Fig. 5A).
Before boosting and at day 5 after boosting, the mice were injected
with a mixture of syngeneic splenocytes pulsed with or without
OVA257-264 peptide, and the elimination of peptide-pulsed
splenocytes (CFSE
hi) was examined by flow cytometry. In the
absence of boosting (Fig. 5A, upper row), strong cytotoxic activity
was only observed following priming with anti-DEC:OVA+anti-
CD40, while after boosting, both primary and secondary responses
were associated with cytotoxic activity (Fig. 5A, lower row).
To determine if the improved effector functions of memory
CD8
+ T cells was associated with protection, mice were
immunized with PBS or anti-DEC:OVA+anti-CD40, and 60 days
later, the mice were challenged with 1610
5 colony-forming units
(CFU) of virulent Listeria monocytogens expressing OVA (LM-OVA)
(Fig. 5B). Mice immunized with anti-DEC:OVA+anti-CD40 were
protected, but mice immunized with PBS were not. Therefore
memory T cells generated by priming with anti-CD40 exert
stronger effector functions and protective immunity.
IL-18 accumulates at the DC:T cell synapse and regulates
antigen-specific CD8
+ T cell proliferation in both primary
and memory responses
IL-18 is a proinflammatory cytokine, which was originally
identified as an IFN-c-inducing factor [19,20]. It has been
reported that memory T cells express high levels IL-18 receptor
(IL-18R) on memory T cells, and that IL-18 can induce bystander
proliferation of memory phenotype CD8
+ T cells [24–26]. Like
IL-1b, IL-18 lacks a secretory signal sequence [27–29]. In the
steady state, IL-18 was expressed in DCs at the protein (Fig. 6A)
and mRNA levels (data not shown). During antigen presentation
to T cells, IL-18 localized to the immunologic synapse (Fig. 6A).
When the OT-I transgenic CD8
+ T cells were cultured with DCs
without peptide, IL-18 was distributed in the cytosol (Fig. 6A,
upper row), but when OT-I T cells were cultured with OVA(257-
264) peptide-pulsed DCs for 30 min, the IL-18 became polarized
IL18 Expands Memory CD8
+TCells
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(Fig. 6A, lower row).
To examine the role of IL-18 in antigen-specific primary and
memory responses, IL-18
2/2 and wild type mice were primed
with PBS or anti-DEC:OVA+anti-CD40 and boosted at day 60
(Fig. 6B and C). In the primary response, significant antigen-
specific CD8
+ T cell proliferation was observed in neither spleen
(Fig. 6B) nor liver (Fig. 6C) of IL-18
2/2 mice. Surprisingly, Ag-
specific T cell proliferation in the secondary response was observed
in IL-18
2/2 mice, but the expansion was delayed compared with
wild type mice. Despite the impaired expansion of memory T cells
in IL-18
2/2 mice, the cells showed direct cytotoxic activity
(Fig. 6D). These results suggest that effector memory develops in
IL-18
2/2 mice, but T cell proliferation both in primary and
memory responses was impaired in the absence of IL-18.
IFN-c stimulates IL-18 production from DCs and
enhances the expansion of memory CD8
+ T cells
It has been reported that IL-18 can stimulate IFN-c production
from lymphocytes including T cells, B cells, and NK cell
[20,30,31]. Interestingly, we found that IL-18 production from
DCs decreased in the absence of IFN-c signaling. Upon
stimulation with LPS, DCs from IFN-c receptor 1(IFN-cR1)
2/2
mice showed much lower IL-18 production than those in wt mice
(Fig. 7A). In vivo administration of anti-CD40 mAb enhanced IL-
18 production from DCs in wt mice but not in IFN-cR1
2/2 mice
Figure 1. DEC-205 targeting in the presence of agonistic anti-CD40 generates memory CD8
+ T cells. (A–D) B6 mice were primed with
PBS or anti-DEC:OVA+anti-CD40, and boosted with anti-DEC:OVA+anti-CD40 at d 60. (A, C) Frequency of OVA-specific CD8
+ T cells in spleen (A) and
liver (C) at day 4, 5, and 7 after booster immunization. Numbers are % of lymphocytes. Representative of five experiments. (B, D) Total number of
OVA-specific CD8
+ T cells per spleen (B) and liver (D) after boosting, where each symbol represents data from different experiments.
doi:10.1371/journal.pone.0002404.g001
IL18 Expands Memory CD8
+TCells
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signaling, in which IFN-c stimulates IL-18 production from DCs.
Recently, Badovinac et al. have shown that priming without
early inflammation, especially in the absence of IFN-c, accelerates
the development of memory CD8
+ T cells [11]. To examine the
role of IFN-c in CD8
+ T cell memory responses, IFN-cRI
2/2 and
wild type mice were primed with PBS or anti-DEC:OVA+anti-
CD40, and boosted with anti-DEC:OVA+ anti-CD40 at day 60
(Fig. 7C, and D). At day 0, 4, and 5 after boosting, splenocytes
were harvested and stained with Kb/OVA257-264 tetramer
(Fig. 7C). Unlike IL-18
2/2 mice, the expansion of tetramer
+
CD8
+ T cells in primary response was normal in IFN-cR1
2/2
mice. However, in the secondary response (mice primed with anti-
DEC:OVA+anti-CD40), the expansion of tetramer
+ CD8
+ T cells
was delayed in IFN-cRI
2/2 mice compared with wild type mice.
Similar kinetics of tetramer
+ CD8
+ cells was observed in the liver
(Fig. 7D). Similar to IL-18
2/2 mice, memory IFN-cRI
2/2 T cells
showed direct cytotoxic activity, which was identical to that of wild
type memory T cells (Fig. 7E and Fig. 5A). Taken together, our
results suggest that IFN-c signaling induces IL-18 production from
DCs and accelerates the proliferation of memory CD8
+ T cells
rather than naı ¨ve T cells.
Discussion
The DEC-205
+ or CD8
+ subset of splenic DCs is known to be
specialized for the presentation of antigens on MHC class I
products [32–34]. We now find that this receptor and subset, when
selectively targeted in vivo with OVA within anti-DEC-205
monoclonal antibody, is able to generate functional CD8
+ memory
T cells depending upon the coadministration of a CD40 signal at
the time of antigen presentation.
Delivery of the OVA antigen to DEC-205
+ DC subset in the
presence of agonistic CD40 mAb induces effector-type memory
CD8
+ T cells that respond to antigen re-encounter rapidly but for
a short-term. These effector cells populate peripheral tissues
including mucosal tissues (lung, intestinal epithelium) and mucosal
associated lymphoid organs (Peyer’s patch and mesenteric lymph
node) both before and after the secondary response. The memory
T cells are functional, producing IL-2, IFN-c, and TNF-a and
exerting direct cytotoxic activity. In addition, DEC-205 targeting
with simultaneous CD40 ligation provides protective immunity.
These data suggest the value of CD40 ligation for DEC-205
+ DCs
to generate protective memory CD8
+ T cells.
We showed that IL-18 accumulates at the DC:T synapse during
antigen-presentation. Although it has been reported that IL-18 can
induce bystander proliferation of memory CD8
+ T cells [25,26],
based on the manner of IL-18 secretion, we have reasoned that IL-
18 might regulate antigen-specific T cell proliferation. As
expected, IL-18 regulates antigen-specific CD8
+ T cell prolifera-
tion both in primary and memory responses. In the absence of IL-
18 signaling, obvious CD8
+ T cell proliferation was not observed
in primary responses, but memory CD8
+ T cells with direct
cytotoxic activity were generated. However, these IL-18
2/2
Figure 2. Characterization of memory CD8
+ T cells following DEC-205 targeting of OVA. (A) Phenotype of OVA-specific memory CD8
+ T
cells at d 60 after priming with anti-DEC:OVA+ anti-CD40. OVA-specific cells were enriched using MACS sorting as described in the methods and
gated as tet
+ CD8
+ cells. Naı ¨ve cells are not tetramer binding cells and were gated as CD44
low CD8
+ cells. (B) Memory CD8
+ T cells were identified in
the indicated tissues: lung, intestine (IEL, LPL), Peyer’s patches (PP), mesenteric lymph nodes (MLN), and spleen at d 60 after priming with anti-
DEC:OVA+anti-CD40. Numbers are % of lymphocytes.
doi:10.1371/journal.pone.0002404.g002
IL18 Expands Memory CD8
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memory T cells. These results suggest that IL-18 is not critical for
generation of memory CD8
+ T cells, but enhances antigen-specific
CD8
+ T cell proliferation both in primary and memory responses.
Although IL-18 was originally identified as a stimulator of IFN-
c production [19,20], our results show an positive loop of IL-18-
IFN-c signaling, in which IFN-c can also stimulate IL-18
production from DCs. Interestingly, IFN-cR1
2/2 mice and IL-
18
2/2 mice show different patterns of T cell proliferation. In the
absence of IFN-c signaling, the expansion of antigen-specific
CD8
+ T cells was normal in primary response but delayed in
secondary response. These results indicate that IFN-c signaling
plays an amplifying role in the acceleration of memory CD8
+ T
cell proliferation. Unlike naı ¨ve CD8
+ T cells, memory CD8
+ T
cells can provide an early source of IFN-c to stimulate more IL-18
production from DCs. Probably, this positive loop of IFN-c-IL-18
signaling may function in recall response rather than in primary
response (Fig. 8).
Our observation that IFN-c accelerates the expansion of
memory CD8
+ T cells seems to conflict with the report by
Figure 3. Proliferative capacity of memory CD8
+ T cells. (A) C57BL/6 mice were primed with PBS or anti-DEC:OVA+anti-CD40, and boosted
with anti-DEC:OVA+anti-CD40 at day 60. At day 2, 4, and 7 after booster immunization, splenocyes were isolated, labeled with CFSE, and then
cultured without (B) or with (C) OVA(257-264) peptide. 3 days after in vitro culture, OVA-specific CD8
+ T cell proliferation was examined by staining
splenocytes with anti-CD8 and K
b/OVA257-264 tetramer. (B) Autonomous proliferation of OVA-specific T cells in the absence of OVA peptide. Plots
were gated on CD8
+ cells. Numbers indicate the percentage of tetramer
+ cells in CD8
+ cells. (C) Ag-driven proliferation of OVA-specific T cell in the
presence of OVA-peptide. Plots were gated on CD8
+ cells. Numbers indicate the percentage of CFSE low tetramer
+ cells in CD8
+ cells.
doi:10.1371/journal.pone.0002404.g003
Figure 4. Memory CD8
+ T cells primed with anti-CD40 produce multiple cytokines. Mice were primed with PBS or anti-DEC:OVA+anti-
CD40, and boosted with anti-DEC:OVA+anti-CD40 at day 60. At the peak of the secondary response (at d 7 after boosting in PBS-primed mice; at d 4
in anti-DEC:OVA+anti-CD40-primed mice), splenocytes were stimulated with OVA(257-264) peptide and the production of IFN-c, IL-2 and TNF-a were
examined by intracellular staining. Representative of two experiments.
doi:10.1371/journal.pone.0002404.g004
IL18 Expands Memory CD8
+TCells
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CD8 T cells [11]. However, there are some differences in the
experimental system. Badovinac et al studied in vitro cultured
mature DCs, while we addressed DC function in vivo. In addition,
they analyzed the memory response at a later time point (at day 6
after boosting), while we examined the kinetics of memory T cells
including earlier time points. We observed more antigen-specific
CD8
+ T cells in wild type mice than IFN-R1c
2/2 mice at day 4,
but the results were the opposite at day 5 and 7 because of the
delayed T cell expansion in IFN-R1c
2/2 mice.
Unlike IL-15 and IL-7, which regulate basal, relatively slow,
homeostatic proliferation of memory T cells during the mainte-
nance phase [4–8], the IFN-c-IL-18 signaling pathway controls
the rapid proliferation of memory CD8
+ T cells during the second
effector phase in concert with antigen-presentation by dendritic
cells. Our findings will help in research to develop vaccines to
induce antigen-specific T cells with a capacity to respond quickly
against viruses and other pathogens.
Materials and Methods
Mice
C57BL/6 (B6) and BALB/c mice were from Taconic Farms
(Germantown, NY). IL-18 -deficient (2/2) mice and IFN-cR1
2/
2 mice (B6 background) were from The Jackson Laboratory.
Females at 8–10 wk of age were used and maintained under
specific pathogen-free conditions in accordance with Institutional
Care and Use Committee guidelines of The Rockefeller
University.
Figure 5. Memory CD8
+ T cells primed with anti-CD40 show
direct cytotoxicity and protective immunity. (A) In vivo CTL
activity. C57BL/6 mice were primed with PBS or anti-DEC:OVA+anti-
CD40, and boosted with PBS or anti-DEC:OVA+anti-CD40 at day 60. 5 d
after boosting, CTL activity was determined by challenge with CFSE
hi
OVA257-264 peptide-loaded splenocytes. Numbers indicate % of
specific killing. (B) Bacterial numbers in spleen at day 4 after infection.
B6 mice were primed with PBS or anti-DEC:OVA+anti-CD40, and 60 d
later, injected i.v. with 1610
5 virulent LM-OVA (four mice per group).
doi:10.1371/journal.pone.0002404.g005
Figure 6. IL-18 accumulates at the DC:T synapse and regulates CD8
+ T cell proliferation. (A) OVA(257-264) peptide-pulsed or unpulsed
DCs were cultured with OT-I transgenic CD8
+ T cells, and stained with anti-IL-18 (green) and anti-CD11c (red). Nuclei were counterstained with DAPI
(blue). (B, C) IL-18
2/2 and wild type mice were primed with PBS or anti-DEC:OVA+anti-CD40, and boosted with anti-DEC:OVA+anti-CD40 at d 60. At
day 0, 4, 5, and 7 after boosting, lymphocytes were isolated from spleen (B) and liver (C), and stained with Kb/OVA257-264 tetramer. (B and C)
Percentage of tetramer
+ cells in CD8
+ T cells. (D) In vivo CTL activity. IL-18
2/2 mice were primed with PBS, or anti-DEC:OVA+anti-CD40, without
booster immunization. At d 60, CTL activity was determined by challenge with CFSE
hi OVA257-264 peptide-loaded splenocytes. Numbers indicate the
% of specific killing. Representative of two experiments.
doi:10.1371/journal.pone.0002404.g006
IL18 Expands Memory CD8
+TCells
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We purchased from BD Biosciences: anti-CD27-FITC, anti-
CD8-APC, anti-CD8-FITC, anti-CD44-PE, anti-CD49d-FITC,
anti-CD62L-FITC, anti-CD122-FITC, anti-IFN-c-PE, anti-IFN-
c-APC, anti-IL-2-PE, and anti-TNF-a-PE; from e-Bioscience:
anti-CD127-FITC and anti-CD127-APC; from Southern Bio-
technology: anti-KLRG-1-FITC, from Cedarlane Labs: anti-
DEC205-PE; and from Santa Cruz: goat polyclonal anti-IL-18.
OVA257-264 (SIINFEKL) peptide was synthesized by the
Proteomics Resource Center (The Rockefeller University).
Generation of Hybrid Antibodies
Anti-DEC:OVA was generated as described [18]. Hybrid
antibodies were transiently expressed in 293T cells using calcium
phosphate. Antibodies were purified on Protein G columns (GE
Healthcare) and subject to detoxification with Detoxi-Gel
TM
Endotoxin Removing Gel (PIERCE). Removal of endotoxin was
verified with Limulus Amebocyte Lysate (LAL) QCL-1000
(CAMBREX).
Immunization
Mice were primed i.p. with 5 mg of anti-DEC:OVA in the
presence of 30 mg of anti-CD40 mAb (clone 1C10).
Figure 7. IFN-c signaling regulates the expansion of memory CD8
+ T cells. (A, B) IL-18 production from DCs. (A) DCs isolated from spleen of
IFN-cR1
2/2 and wild type mice were stimulated with LPS in the presence or absence of IFN-c for 24 hr. (B) IFN-cR1
2/2 and wild type mice were
injected with PBS or anti-CD40 and 1hr later, DCs were isolated and cultured in the presence of LPS for 24 hr. The culture supernatants were
harvested and IL-18 production was measured by ELISA. (C, D) IFN-cR1
2/2 and wild type mice were primed with PBS or anti-DEC:OVA+anti-CD40, and
boosted with anti-DEC:OVA+anti-CD40 at day 60. At day 0, 4, 5, and 7 after boosting, lymphocytes were isolated from spleen (C) and liver (D), and
stained with Kb/OVA257-264 tetramer. (C and D)Percentage of tetramer
+ cells in CD8
+ T cells. (E) In vivo CTL activity. IFN-cRI
2/2 mice were primed
with PBS or anti-DEC:OVA+anti-CD40, without booster immunization. At d 60, CTL activity was determined by challenge with CFSE
hi OVA257-264
peptide-loaded splenocytes. Numbers indicate the % of specific killing. Representative of two experiments.
doi:10.1371/journal.pone.0002404.g007
Figure 8. Model of a positive regulatory loop of IFN-c-IL-18
signaling in memory CD8
+ T cell expansion. Unlike naı ¨ve CD8
+ T
cells, memory CD8
+ T cells can provide an early source of IFN-c to
stimulate more IL-18 production from DCs. This positive loop of IFN-c-
IL-18 signaling may play an amplifying role in the acceleration of CD8
+ T
cell expansion in memory response rather than in primary response.
doi:10.1371/journal.pone.0002404.g008
IL18 Expands Memory CD8
+TCells
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L. monocytogenes expressing the OVA gene (LM-OVA) was
provided by Dr. Eric G. Pamer (Sloan-Kettering Institute, New
York, NY) and Dr. Hao Shen (University of Pennsylvania School
of Medicine, Philadelphia, PA). The bacteria were grown in brain
heart infusion (BHI) broth and injected i.v. Colony-forming units
were assessed by plating 10-fold dilutions on BHI agar containing
1 mg/ml erythromycin.
Isolation of lymphocytes from nonlymphoid tissues
Intrahepatic lymphocytes were isolated from livers as described
[35]. Small intestinal intraepithelial lymphocytes (IEL) and lamina
propria lymphocytes (LPL) were isolated as described [36,37]. For
preparation of lung lymphocytes, the lungs were perfused with
10 ml of PBS, removed, minced and incubated in 1 ml of
RPMI1640 with 5% fetal calf serum (FCS) containing 125 U/ml
of collagenase D (Roche) and 60 U/ml of Dnase I (Roche) for
25 min at 37uC. Mononuclear cells were purified by Percoll
gradient centrifugation.
Isolation of CD11
+ DCs and TCR transgenic CD8
+ T cells
DCs were purified from collagenase-trated spleens by positive
selection with anti-CD11c microbeads (Miltenyi Biotech). T cells
were purified from spleens and lymph nodes of TCR Tg mice
using T cell enrichment columns (R&D). T cells were incubated
with anti-CD4 microbeads and CD8 T cells purified by negative
selection with MACS separation columns (Miltenyi Biotech).
MHC tetramer staining
Lymphocytes (1610
6) were blocked Fc block (clone 2.4G2, BD
Biosciences) and unlabeled streptavidin (Molecular Probes). Cells
were washed and then stained with K
b/OVA257-264 tetramer
(kindly provided by Dr. E. Pamer) and anti-CD8 in combination
with anti-CD27, anti-CD44, anti-CD49d, anti-CD62L, anti-
CD122, anti-CD127, or anti-KLRG-1, for 1 hr at 4uC.
200,000–400,000 events were acquired on a FACSCalibur
TM
(Becton Dickinson). Data were analyzed using CellQuest
TM
(Becton Dickinson) and FlowJo (TreeStar) software.
Enrichment of tetramer
+ cells
T cells were purified from collagenase-treated spleens by
negative selection using T cell enrichment columns (R&D). T
cells were incubated with PE-labeled K
b/OVA257-264 tetramer,
followed by anti-PE microbeads (Miltenyi Biotech).
Intracellular cytokine staining
Lymphocytes (5610
6) were incubated with 2 mM of OVA (257-
264) peptide in the presence of 2 mg/ml of anti-CD28 mAb (clone
37.51) for 6 hr. Brefeldin A (10 mg/ml; Sigma-Aldrich) was added
for the last 4 hr of culture. After surface staining with anti-CD8
and anti-CD62L, cells were stained with anti-IFN-c using Cytofix/
Cytoperm kit (BD Biosciences) according to manufacturer
instructions. In some experiments, cells were stained with anti-
CD8 and anti-IFN-c in combination with anti-IL-2 or TNF-a.2 –
4610
5 events were acquired on a FACSCalibur
TM (Becton
Dickinson) as described above.
Ex vivo proliferation
Splenocytes at 1610
7 cells/ml were labeled with 0.05 mM
CFSE for 10 min at 37uC. Cells were washed and cultured with or
without 2 mM of OVA (257-264) peptide. After 60 hr, cells were
stained with anti-CD8 and K
b/OVA257-264 tetramer and
evaluated by flow cytometry for CFSE dilution.
In vivo CTL assay
C57BL/6 splenocytes were incubated for 1 hr at 37uC with or
without 10 mM of OVA (257-264) peptide and labeled for 10 min
at 37uC with carboxyfluorescein diacetate succinimidyl diester
(CFSE, Molecular Probes) at 5 mM (CFSE
hi, peptide-labeled
splenocytes) or 0.5 mM (CFSE
lo, splenocytes without peptide).
Immunized or naı ¨ve control mice were injected i.v. with 10
7 cells
of each fraction. Splenocytes were isolated 18 hr later, and
analyzed by flow cytometry. Specific cytotoxicity was calculated
with the following equation: cytotoxicity (%)=[12(ratio immune/
ratio naive)]6100. Ratio=percentage of CFSE
hi/percentage of
CFSE
lo.
Conjugate formation and immunofluorescene
Conjugates between T cells and DCs were formed by mixing
OT-I transgenic CD8 T cells and OVA (257-264) peptide-pulsed
(1 mg/ml) or unpulsed DCs at a 2:1 ratio and a quick
centrifugation at 3006g for 30 sec to initiate cell–cell contact.
Cells were incubated at 37uC, 5% CO2 for 30 min. Cells were
fixed and permeabilized with Cytofix/Cytoperm (BD Biosciences)
for 20 min at room temperature, and then stained with goat
polyclonal anti-IL-18 in combination with hamster anti-CD11c-
biotin, followed by anti-goat IgG-FITC with streptavidin-Cy3.
Cells were treated with DAPI to stain nuclei and analyzed in an
Olympus IX70 microscope.
ELISA
Mice were injected i.p. with or without 30 mg of anti-CD40
mAb (clone 1C10) and1 hr later, DCs were isolated from spleen.
The DCs (5610
5/well) were stimulated with 500 ng/ml LPS for
24 hr. The culture supernatants were harvested and IL-18
concentration was determined using a commercial ELISA lit
(MBL).
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